|
| |
Cervix NeoplasmsDownload PDF containing detailed information.
Recent Publications on Cervix Neoplasms: |  |
Losses of expression of the antigens A, Lea and Lex and over-expression of Ley in carcinomas and HG-SIL of the uterine cervix.
ABSTRACT: BACKGROUND: The glycosylation of a great number of molecules,... | 13th September, 2008
| Area de Patologia, Universidad Rey Juan Carlos, Madrid, Spain.
| Diagn Pathol. 2008 Sep 11;3:38.
DOI Direct Link |
[Intraarterial chemotherapy for cervix neoplasms]
ABSTRACT: BACKGROUND: The glycosylation of a great number of molecules,... | 26th January, 2005
| Department of Obstetrics and Gynecology, Yokohama City University School
| Nippon Rinsho. 2004 Oct;62 Suppl 10:196-200.
|
[Neoadjuvant chemotherapy for cervix neoplasms]
ABSTRACT: BACKGROUND: The glycosylation of a great number of molecules,... | 26th January, 2005
| Department of Obstetrics and Gynecology, Aizawa Hospital.
| Nippon Rinsho. 2004 Oct;62 Suppl 10:192-5.
|
[Doppler ultrasonography in assessing the effectiveness of preoperative radiochemotherapy in patients with uterine cervix neoplasms]
ABSTRACT: BACKGROUND: The glycosylation of a great number of molecules,... | 20th June, 2003
|
| Vopr Onkol. 2003;49(2):232-4.
|
[Changes of antioxidant parameters correlating with clinical regression of uterine cervix neoplasms]
In order to identify processes associated with clinically-proven... | 13th May, 2003
| Research Institute of Oncology, Ministry of Health of the RF,
| Vopr Onkol. 2003;49(1):99-102.
|
→View more research publications. |
Press Releases About Cervix Neoplasms:
|
 |
| Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients |
31st May, 2009 |
Eli Lilly and Company |
ORLANDO, Fla., May 31 /PRNewswire-FirstCall/ -- Eli Lilly and Company announced today that Phase III trial data showed the addition of Lilly's GEMZAR(R) (gemcitabine HCl for injection) to the
|
| Ipsogen Expands its US Market Presence Through Licensing Agreement With ARUP Laboratories for the Commercialization of JAK2 Molecular Diagnostic Assays |
4th May, 2009 |
Ipsogen SA |
MARSEILLE, France, May 4 /PRNewswire-FirstCall/ -- Ipsogen SA (Alternext
- FR0010626028 - ALIPS), a molecular diagnostic company specialized in the
development, the manufacturing and the
|
| New NCCN Guidelines for Primary Cutaneous B-Cell Lymphoma and Updates to NCCN Guidelines for Non-Hodgkin's Lymphomas |
13th March, 2009 |
National Comprehensive Cancer Network |
NCCN presented new NCCN Clinical Practice Guidelines in Oncology(TM) for Primary Cutaneous B-Cell Lymphoma as well as important updates to the NCCN Guidelines for Non-Hodgkin's Lymphomas at the
|
| Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting |
6th December, 2008 |
American Society of Hematology |
SAN FRANCISCO, Dec. 6 /PRNewswire-USNewswire/ -- Four studies highlighting late-breaking research advances in the treatment of cancer and sickle cell disease will be presented today at the 50th Annual
|
BioPortfolio Ltd. offers e-mail and postal lists for Cervix Neoplasms scientists - we have details of around 425 individuals working on Cervix Neoplasms .
This page has been viewed 286 times
Recent Search Terms used to find this page: cervix neoplasms | .
Browse BioPortfolio's InDepth service - alphabetically:
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
or by Most Publications, recently searched for, or
most viewed.
Search for Cervix Neoplasms across BioPortfolio, or for Cervix Neoplasms Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH.
Thumbshots from Thumbshots.org
|
